The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

Bangalore: Biocon has announced the appointment of Ekta Agarwal as the Interim Company Secretary and Compliance Officer ...

Clinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Bhosale's top pick is Prestige Estates Projects with a stoploss of Rs 1,600. "The stock is looking very positive on the daily ...

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

Expert CA Rudramurthy BV suggests a bullish stance. He recommends buying on dips, especially in pharma stocks like Glenmark, ...

The company is seeking regulatory approval of generic Ozempic by September from Canadian authorities, along with other ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...